You need to be logged in to see the full monograph.

USE OF SERTRALINE IN PREGNANCY

Date of issue: November 2026, Version: 4

bumps logo
A corresponding patient information leaflet on USE OF SERTRALINE IN PREGNANCY is available.

Sertraline is a selective serotonin reuptake inhibitor (SSRI) used in the treatment of depression, obsessive-compulsive disorder, post-traumatic stress disorder, social anxiety disorder, and panic disorder with or without agoraphobia.

Treatment of mental health conditions during pregnancy should be optimised to facilitate quality of life, sleep, and ability to carry out activities of daily living. Poorly controlled mental health poses risks to both the woman and her unborn baby. Risk of postpartum depression/psychosis is increased in women with poorly controlled mental health conditions during pregnancy. SSRIs should therefore not be withheld solely due to pregnancy.

Most data on gestational sertraline exposure do not show statistically significant increased risks of overall malformation or cardiac malformation. Where studies have reported an increased risk of cardiac malformation, the absolute increase is small (up to ~1.4% compared to ~0.8% in the background population).

Evidence regarding miscarriage, intrauterine death, preterm birth, low birth weight and neurodevelopmental delay is generally reassuring but limited.

Exposure to SSRIs beyond 20 weeks’ gestation has been linked to a small increased risk of persistent pulmonary hypertension of the newborn (PPHN). The estimated absolute risk is <0.4% (background 0.1–0.2%). Although uncommon, the potential severity of PPHN warrants discussion before prescribing.

SSRI exposure shortly before delivery is associated with transient neonatal withdrawal symptoms. Hospital delivery is therefore recommended in case of the need for neonatal monitoring for central nervous system, motor, respiratory, and gastrointestinal signs.

The MHRA advises a small increased risk of postpartum haemorrhage (PPH) following SSRI/SNRI use in the month before delivery. Some studies suggest up to a 1.3 fold increase, equating to an absolute risk of 13–20% (background 10–15%). Decisions about continuing treatment should balance this against the risk of maternal relapse. Pregnant women with risk factors for venous thromboembolism should continue appropriate heparin prophylaxis.

Mental health conditions should be managed appropriately in pregnancy. Sertraline may be suitable following individualised risk–benefit assessment. For patients already stable on sertraline, the risks of stopping, switching or reducing the dose should be weighed carefully against relapse risk. If continued, the lowest effective dose should be used.

Exposure to sertraline at any stage of pregnancy is not usually considered grounds for pregnancy termination or for additional fetal monitoring. However, other individual risk factors may independently increase the likelihood of adverse outcomes, and clinicians should ensure these are carefully considered during case specific risk assessments.

This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.

If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.

If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.

Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from UKTIS.org to ensure you are using the most up-to-date version.